Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines
| Autor: | Detlef Grunert, Devayani Kolhe, Juan C. Tejedor, Yaela Baine, Jerzy Brzostek, Marie Van der Wielen, Ryszard Konior |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Microbiology (medical) Blood Bactericidal Activity Heptavalent Pneumococcal Conjugate Vaccine Clinical Biochemistry Immunology Enzyme-Linked Immunosorbent Assay Neisseria meningitidis Serogroup C Diphtheria-Tetanus-acellular Pertussis Vaccines complex mixtures Pneumococcal conjugate vaccine Pneumococcal Vaccines 03 medical and health sciences 0302 clinical medicine Conjugate vaccine 030225 pediatrics Tetanus Toxoid medicine Humans Immunology and Allergy 030212 general & internal medicine Child Haemophilus Vaccines Randomized Controlled Trials as Topic Vaccines Vaccines Conjugate business.industry Diphtheria Toxoid Infant Vaccine efficacy medicine.disease Antibodies Bacterial Virology Vaccination Child Preschool Female business Follow-Up Studies medicine.drug |
| Zdroj: | Clinical and Vaccine Immunology : CVI Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid |
| ISSN: | 1556-679X 1556-6811 |
| DOI: | 10.1128/cvi.00057-16 |
| Popis: | We evaluated antibody persistence in children up to 5 years after administration of a combined Haemophilus influenzae type b (Hib)- Neisseria meningitidis serogroup C (MenC)-tetanus toxoid (TT) conjugate vaccine coadministered with a pneumococcal conjugate vaccine. This is the follow-up study of a randomized trial (ClinicalTrials.gov registration no. NCT00334334/00463437) in which healthy children were vaccinated (primary vaccinations at 2, 4, and 6 months of age and booster vaccination at 11 to 18 months of age) with Hib-MenC-TT or a control MenC conjugate vaccine, coadministered with diphtheria-tetanus-acellular pertussis (DTPa)-based combination vaccines (DTPa/Hib for control groups) and a pneumococcal conjugate vaccine (10-valent pneumococcal nontypeable H. influenzae protein D conjugate vaccine [PHiD-CV] or 7-valent cross-reacting material 197 [CRM 197 ] conjugate vaccine [7vCRM]). MenC antibody titers were measured with a serum bactericidal antibody (SBA) assay using rabbit complement (i.e., rabbit SBA [rSBA]), and antibodies against Hib polyribosylribitol phosphate (PRP) were measured with an enzyme-linked immunosorbent assay. Antibody persistence up to 5 years after booster vaccination is reported for 530 children ∼6 years of age. The percentages of children with seroprotective rSBA-MenC titers were between 24.2% and 40.1% in all groups approximately 5 years after booster vaccination. More than 98.5% of children in each group retained seroprotective anti-PRP concentrations. No vaccine-related serious adverse events and no events related to a lack of vaccine efficacy were reported. Approximately 5 years after booster vaccination, the majority of children retained seroprotective anti-PRP antibody concentrations. The percentage of children retaining seroprotective rSBA-MenC titers was low (≤40%), suggesting that a significant proportion of children may be unprotected against MenC disease. (This study has been registered at ClinicalTrials.gov under registration no. NCT00891176.) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|